Octreotid-Mepha LA, subst sèche 20 mg c solv , flac 1 pce
7680671540024
CH-67154
H01CB02
Reimbursement limitations:
SANDOSTATIN
Tumeurs du système endocrine gastroentéropancréatique.
Acromégalie qui ne réagit pas ou pas suffisamment à d'autres …
1 / 3
google
Details
- Product number
- -
- CPT
- -
- Packaging group
- -
- Unit
- -
Official Swissmedic V2 data
Additional information from the official database
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRS
|
20.0 MG | Substance | Wirkstoff (Principe actif) |
|
SOLV
|
- | Substance | HNIDK |
|
SOLV
|
1.512 MG | Substance | HBESI |
|
PRS
|
- | Substance | WIZUS |
|
PRS
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
PRS
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
|
SOLV
|
- | Substance | HNIDK |
Authorization holder
Mepha Pharma AG
4051 Basel
Authorization information
- Swissmedic authorization number
- 67154
- Drug name
- Octreotid-Mepha LA, Pulver und Lösungsmittel zur Herstellung einer Depot-Injektionssuspension
- Galenic form
- PULMS
- ATC Code
- H01CB02
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 19/07/2019
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.2.
- Domain
- Human medicine
Packaging details
- Description (FR)
- OCTREOTID Mepha LA subst sèche 20 mg c solv
- Description (DE)
- OCTREOTID Mepha LA Trockensub 20 mg c Solv
- Narcotic (BTM)
- No